Table 5.
Cox regression analysis of progression-free survival in patients with locally advanced and oligometastatic nasopharyngeal carcinoma.
| Progression-Free Survival | |||||||
|---|---|---|---|---|---|---|---|
| Univariate Analysis | Multivariate Analysis | ||||||
| HR | 95% CI | p | HR | 95% CI | p | ||
| Age | 0.87 | 0.01–0.65 | 0.017 | Age | 0.31 | 0.03–2.84 | 0.299 |
| Sex | 0.51 | 0.17–1.51 | 0.223 | Sex | - | - | - |
| Smoking | 1.30 | 0.54–3.12 | 0.558 | Smoking | - | - | - |
| Alcohol | 0.13 | 0.02–0.96 | 0.046 | Alcohol | 0.49 | 0.04–5.57 | 0.566 |
| EBV-DNA | 3.32 | 1.28–8.62 | 0.014 | EBV-DNA | 1.05 | 0.26–4.28 | 0.941 |
| ECOG PS | 2.89 | 0.96–8.72 | 0.060 | ECOG PS | - | - | - |
| Clinical stage | 2.66 | 1.10–6.40 | 0.029 | Clinical stage | 0.79 | 0.28–2.30 | 0.671 |
| Disease burden | 2.31 | 0.88–6.12 | 0.091 | Disease burden | - | - | - |
| MLR | 22.65 | 16.53–78.64 | <0.001 | MLR | 14.77 | 1.92–113.45 | 0.010 |
| MAR | 7.68 | 2.95–20.03 | <0.001 | MAR | 1.50 | 0.29–7.69 | 0.625 |
| CD47 | 11.80 | 3.86–36.10 | <0.001 | CD47 | 1.85 | 0.12–28.78 | 0.574 |
| CD68 | 5.39 | 1.95–14.90 | 0.001 | CD68 | 2.52 | 0.30–20.95 | 0.394 |
| CD163 | 3.21 | 1.17–8.84 | 0.024 | CD163 | 0.14 | 0.02–1.33 | 0.087 |
Abbreviations: EBV, Epstein–Barr virus; ECOG PS, Eastern Cooperative Oncology Group Performance Status; MLR, monocyte-to-lymphocyte ratio; MAR, monocyte-to-albumin ratio.